Nuvara Therapeutics is a clinical-stage biotech company with a disruptive
approach to modulating epithelial transmembrane proteins to treat disease.

Nuvara Therapeutics originated from the pioneering work of entrinsic bioscience, LLC

Leverages sister company R&D assets and personnel to significantly reduce capital requirements

Full worldwide development and commercialization rights for all therapeutic applications

Originated from $40 million NASA|BARDA grant to study therapies directed at intestinal irradiation and the accompanying toxic gut syndrome (leaky gut and diarrhea)